Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
暂无分享，去创建一个
[1] L. Ferrucci,et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.
[2] W. Catalona,et al. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. , 2005, The Journal of urology.
[3] A. Renshaw,et al. Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .
[4] P. Walsh,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.
[5] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[6] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[7] D. Bates,et al. Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.
[8] I. Rossman,et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging , 1986 .
[9] David Arenberg,et al. Normal Human Aging: The Baltimore Longitudinal Study on Aging , 1984 .